Home›Deferoxamine Mesylate

Deferoxamine Mesylate

Also known as: Deferoxamine

Route: Intramuscular, Intravenous, Subcutaneous

Check Deferoxamine Mesylate Interactions →

2 interactions on record

Deferoxamine Mesylate has 2 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Prochlorperazine, Gallium-67. Patients taking Deferoxamine Mesylate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Major: 1
Moderate: 1

Major (1)

Deferoxamine Mesylate + Prochlorperazine— Concurrent treatment may lead to temporary impairment of consciousness.

Moderate (1)

Deferoxamine Mesylate + Gallium-67— Imaging results may be distorted due to rapid urinary excretion of deferoxamine-bound gallium-67. Discontinue deferoxami…

Deferoxamine Mesylate + Prochlorperazine⚠️Major

Concurrent treatment may lead to temporary impairment of consciousness.

Deferoxamine Mesylate + Gallium-67🟡Moderate

Imaging results may be distorted due to rapid urinary excretion of deferoxamine-bound gallium-67. Discontinue deferoxamine 48 hours prior to scintigraphy.

Contraindications

4 CONTRAINDICATIONS Deferoxamine Mesylate for Injection is contraindicated in patients with: • A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see Description ( 11 )] . Reactions have included anaphylaxis [see Warnings and Precautions ( 5.1 )] . • Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see Warnings and Precautions ( 5.3 )] . • Known hypersensitivity to the active substance. ( 4 ) • Patients with severe renal disease or anuria. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are no available data on Deferoxamine Mesylate for Injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes. In animal reproduction studies subcutaneous administration of deferoxamine to pregnant animals (mice or rabbits) during organogenesis at doses approximately ≥0.2- (mice) and ≥0.7 (rabbits) times the maximum recommended human dose resulted in maternal toxicity and adverse developmental outcomes (see Data ) . Advise pregnant women of the potential risk to a fetus. Consider the benefits and risks of Deferoxamine Mesylate for Injection for the mother and possible risks to the fetus when prescribing Deferoxamine Mesylate for Injection to a pregnant woman. The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal developmental study in mice, pregnant animals administered subcutaneous doses of deferoxamine at 180, and 540 mg/kg/day from gestation day 7 to gestation day 12 resulted in a dose dependent delay and irregularities of fetal skeletal maturation at doses ≥0.2 times the MRHD. At the highest dose of 540 mg/kg, in 1/23 fetuses had a unilateral lesion to the eye lens (approximately 0.5 times the MRHD). In the embryo-fetal developmental studies in rabbits, pregnant animals administered subcutaneous doses of deferoxamine either 200 mg/kg or 200, 300, and 540 mg/kg from gestation day 6 to gestation day 14 resulted in maternal toxicity and embryo-fetal developmental effects at 0.7 times the MRHD). Maternal toxicity included reduced fetal body weights and embryo-fetal effects included malformat

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.